Earnings History Data for Xeris Biopharma Holdings, Inc. (XERS) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings is a biopharmaceutical company. It involved in developing and commercializing therapies for patient in endocrinology, neurology and gastroenterology. The company's principal product includes Gvoke(R), a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and Keveyis(R), the first and only FDA-approved therapy for primary periodic paralysis. Xeris Biopharma Holdings, formerly known as Xeris Pharmaceuticals Inc., is headquartered in Chicago, IL.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 08-11-2024 | PM | XERS | Xeris Biopharma Holdings, Inc. | 497.66 | -0.06 | -0.09 | -0.09 | Xeris Pharmaceuticals GAAP EPS of -$0.11 misses by $0.02, revenue of $54.3M beats by $2.87M [11/8/2024 7:11 AM] |
3.44 | 0.08 (2.23%) |
3.40 | 0.04 (1.19%) |
1.46 - 3.64 | 6,249,088 | 1,540,000 | 121,510 | ||
| 08-08-2024 | PM | XERS | Xeris Biopharma Holdings, Inc. | 335.06 | -0.10 | -0.11 | -0.14 | Xeris Pharmaceuticals GAAP EPS of -$0.10 beats by $0.01, revenue of $48.07M beats by $2.26M [8/8/2024 7:11 AM] |
2.20 | 0.07 (3.29%) |
2.18 | 0.05 (2.35%) |
1.46 - 3.26 | 2,920,180 | 1,420,000 | 41,884 | ||
| 09-05-2024 | PM | XERS | Xeris Biopharma Holdings, Inc. | 264.05 | -0.14 | -0.12 | -0.12 | Xeris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.02, revenue of $40.64M misses by $1.17M [5/9/2024 7:16 AM] |
1.87 | 0.02 (1.08%) |
1.80 | -0.05 (-2.70%) |
1.46 - 3.26 | 1,466,686 | 1,050,000 | 29,752 | ||
| 06-03-2024 | PM | XERS | Xeris Biopharma Holdings, Inc. | 439.24 | -0.10 | -0.09 | -0.10 | Xeris Pharmaceuticals GAAP EPS of -$0.10 in-line, revenue of $44.39M beats by $0.84M [3/6/2024 7:03 AM] |
2.48 | -0.60 (-19.64%) |
3.02 | -0.06 (-1.95%) |
1.13 - 3.26 | 7,904,083 | 2,210,000 | 266,190 | ||
| 09-11-2023 | PM | XERS | Xeris Biopharma Holdings, Inc. | 258.87 | -0.09 | -0.12 | -0.14 | Xeris Pharmaceuticals GAAP EPS of -$0.09 beats by $0.03, revenue of $48.32M beats by $7.24M [11/9/2023 7:03 AM] |
1.80 | -0.18 (-8.84%) |
2.03 | 0.05 (2.53%) |
0.97 - 3.07 | 2,907,507 | 930,000 | 93,305 | ||
| 08-08-2023 | PM | XERS | Xeris Biopharma Holdings, Inc. | 362.50 | -0.14 | -0.13 | -0.19 | Xeris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.01, revenue of $38.01M beats by $3.17M [8/8/2023 7:06 AM] |
2.58 | 0.09 (3.82%) |
2.41 | -0.08 (-3.21%) |
0.97 - 3.07 | 1,593,495 | 930,000 | 57,522 | ||
| 09-05-2023 | PM | 7:00 AM ET (May 9) |
XERS | Xeris Pharmaceuticals | 0.00 | -0.12 | -0.17 | 0.00 | Xeris Pharmaceuticals GAAP EPS of -$0.12 beats by $0.05, revenue of $33.2M beats by $2.43M [5/9/2023 7:03 AM] |
2.73 | 0.33 (13.54%) |
2.44 | 0.04 (1.67%) |
0.97 - 2.73 | 3,107,337 | 1,130,000 | 41,234 | |
| 08-03-2023 | PM | 7:00 AM ET (Mar 8) |
XERS | Xeris Pharmaceuticals | 0.00 | -0.10 | -0.16 | 0.00 | Xeris Pharmaceuticals GAAP EPS of -$0.10 beats by $0.06, revenue of $32.54M beats by $1.5M [3/8/2023 6:25 AM] |
1.35 | -0.18 (-11.76%) |
1.45 | -0.08 (-5.23%) |
0.97 - 2.95 | 1,723,231 | 1,180,000 | 108,007 | |
| 09-11-2022 | PM | 7:00 AM ET (Nov 9) |
XERS | Xeris Pharmaceuticals | 0.00 | -0.14 | -0.17 | 0.00 | Xeris Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01, revenue of $29.6M beats by $0.48M [11/9/2022 7:11 AM] |
1.49 | -0.01 (-0.67%) |
1.59 | 0.09 (6.00%) |
1.19 - 3.17 | 893,368 | 490,000 | 37,920 | |
| 10-08-2022 | PM | 7:00 AM ET (Aug 10) |
XERS | Xeris Pharmaceuticals | 0.00 | -0.19 | -0.23 | 0.00 | Xeris Pharmaceuticals GAAP EPS of -$0.19 beats by $0.04, revenue of $25.31M misses by $0.22M [8/10/2022 7:04 AM] |
1.92 | 0.22 (12.94%) |
1.74 | 0.04 (2.35%) |
1.25 - 3.17 | 1,347,041 | 840,000 | 27,213 | |
| 11-05-2022 | PM | 7:00 AM ET (May 11) |
XERS | Xeris Pharmaceuticals | 0.00 | -0.25 | -0.24 | 0.00 | Xeris Pharmaceuticals GAAP EPS of -$0.25 in-line, net product revenue of $21.91M misses by $1.48M [5/11/2022 7:06 AM] |
1.65 | -0.14 (-8.10%) |
1.89 | 0.10 (5.59%) |
1.54 - 4.98 | 2,554,378 | 1,620,000 | 11,061 | |
|
||||||||||||||||||
| 10-03-2022 | PM | 7:00 AM ET (Mar 10) |
XERS | Xeris Pharmaceuticals | 0.00 | -0.42 | -0.21 | 0.00 | Xeris Pharmaceuticals GAAP EPS of -$0.42 misses by $0.14, net product revenue of $21.36M [3/10/2022 7:06 AM] |
2.46 | -0.02 (-0.61%) |
2.34 | -0.13 (-5.26%) |
1.77 - 5.09 | 1,475,590 | 3,108,270 | 0 | |
|
||||||||||||||||||
| 05-08-2021 | PM | 7:00 AM ET (Aug 5) |
XERS | Xeris Pharmaceuticals, Inc. | 196.83 | -0.41 | -0.31 | -0.63 | Xeris Pharmaceuticals EPS misses by $0.14, misses on revenue [8/5/2021 7:08 AM] |
2.48 | -0.37 (-12.98%) |
2.48 | 0.0 (0.00%) |
2.20 - 7.94 | 6,615,225 | 1,180,000 | 300 | |
| 13-05-2021 | PM | 7:00 AM ET (May 13) |
XERS | Xeris Pharmaceuticals, Inc. | 226.86 | -0.30 | -0.31 | -0.89 | Xeris Pharmaceuticals EPS beats by $0.06, beats on revenue [5/13/2021 7:06 AM] |
3.19 | -0.14 (-4.20%) |
3.19 | 0.0 (0.00%) |
2.45 - 7.94 | 3,954,871 | 2,160,000 | 23,548 | |
| 09-03-2021 | PM | 7:00 AM ET (Mar 9) |
XERS | Xeris Pharmaceuticals, Inc. | 237.05 | -0.41 | -0.39 | -1.23 | Xeris Pharmaceuticals EPS misses by $0.01, misses on revenue [3/9/2021 7:03 AM] |
4.57 | -0.15 (-3.18%) |
4.33 | -0.39 (-8.26%) |
1.42 - 7.94 | 4,590,862 | 2,518,324 | 142,673 | |
|
||||||||||||||||||
| 09-11-2020 | PM | 7:00 AM ET (Nov 9) |
XERS | Xeris Pharmaceuticals, Inc. | 250.38 | -0.35 | -0.54 | -1.22 | Xeris Pharmaceuticals EPS beats by $0.19, beats on revenue [11/9/2020 7:25 AM] |
5.72 | 0.27 (4.95%) |
5.98 | 0.53 (9.72%) |
1.42 - 9.69 | 2,481,513 | 1,294,694 | 207,316 | |
|
|
||||||||||||||||||
| 10-08-2020 | PM | 7:00 AM ET (Aug 10) |
XERS | Xeris Pharmaceuticals, Inc. | 147.54 | -0.63 | -0.71 | -1.28 | Xeris Pharmaceuticals EPS beats by $0.09, beats on revenue [8/10/2020 7:03 AM] |
3.50 | 0.16 (4.63%) |
3.49 | 0.14 (4.18%) |
1.42 - 12.50 | 3,438,005 | 2,867,491 | 321,785 | |
|
|
||||||||||||||||||